title: Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.
abstract: OBJECTIVE
  Delineate the feasibility of simultaneous, dual selective "targeted" chemotherapeutic delivery and determine if this molecular strategy can promote higher levels anti-neoplastic cytotoxicity than if only one covalent immunochemotherapeutic is selectively "targeted" for delivery at a single membrane associated receptor over-expressed by chemotherapeutic-resistant mammary adenocarcinoma.
  
  
  METHODS
  Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/neuutilizing a rapid multi-phase synthetic organic chemistry reaction scheme. Determination that 96% or greater gemcitabine or epirubicin content was covalently bond to immunoglobulin fractions following size separation by micro-scale column chromatography was established by methanol precipitation analysis. Residual binding-avidity of gemcitabine-(C4-amide)-[anti-EG-FR] applied in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu] was determined by cell-ELIZA utilizing chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations. Lack of fragmentation or polymerization was validated by SDS-PAGE/immunodetection/chemiluminescent autoradiography. Anti-neoplastic cytotoxic potency was determined by vitality stain analysis of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayers known to uniquely over-express EGFR (2 × 105/cell) and HER2/neu(1 × 106/cell) receptor complexes. The covalent immunochemotherapeutics gemcitabine-(C4-amide)-[anti-EGFR] and epirubicin-(C3-amide)-[anti-HER2/neu] were applied simultaneously in dual-combination to determine their capacity to collectively evoke elevated levels of anti-neoplastic cytotoxicity. Lastly, the tubulin/microtubule inhibitor mebendazole evaluated to determine if it's potential to complemented the anti-neoplastic cytotoxic properties of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu].
  
  
  RESULTS
  Dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone. The benzimidazole microtubule/tubulin inhibitor, mebendazole complemented the anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu].
  
  
  CONCLUSIONS
  The dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced higher levels of selectively "targeted" anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) than either covalent immunochemotherapeutic alone. The benzimidazole tubulin/microtubule inhibitor, mebendazole also possessed anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) and complemented the potency and efficacy of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu].
authors.affiliation: Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
authors.forename: C P
authors.initials: CP
authors.lastname: Coyne
authors.affiliation: Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
authors.forename: Toni
authors.initials: T
authors.lastname: Jones
authors.affiliation: Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
authors.forename: Ryan
authors.initials: R
authors.lastname: Bear
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1928-35
references.pmid: 16551879
references.citation: Jpn J Clin Oncol. 2006 Apr;36(4):207-11
references.pmid: 16611663
references.citation: Br J Pharmacol. 2008 Sep;155(2):185-97
references.pmid: 18574456
references.citation: Anticancer Agents Med Chem. 2008 Jun;8(5):488-96
references.pmid: 18537532
references.citation: Drug Metab Dispos. 2001 Mar;29(3):313-8
references.pmid: 11181501
references.citation: ACS Appl Mater Interfaces. 2010 May;2(5):1384-9
references.pmid: 20420365
references.citation: J Natl Cancer Inst. 1988 Sep 21;80(14):1154-9
references.pmid: 3261803
references.citation: Eur J Pharm Sci. 2009 Jun 28;37(3-4):405-12
references.pmid: 19491032
references.citation: Anticancer Drugs. 2009 Nov;20(10):851-5
references.pmid: 19826350
references.citation: Cancer Res. 1999 Jan 1;59(1):115-21
references.pmid: 9892195
references.citation: Leuk Res. 1996 Jan;20(1):37-45
references.pmid: 8632676
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2152-62
references.pmid: 19671734
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):136-42
references.pmid: 16584929
references.citation: Pharm Res. 2001 Jan;18(1):29-38
references.pmid: 11336350
references.citation: Biol Direct. 2011 Jan 26;6:5
references.pmid: 21269489
references.citation: Biomaterials. 2008 Oct;29(28):3856-65
references.pmid: 18606445
references.citation: J Control Release. 2006 Jan 10;110(2):362-369
references.pmid: 16303202
references.citation: J Cancer Ther. 2012 Oct;3(5A):689-711
references.pmid: 26225216
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Anticancer Res. 1990 Mar-Apr;10(2A):353-7
references.pmid: 2346308
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6
references.pmid: 21321214
references.citation: Expert Opin Drug Saf. 2011 May;10(3):407-17
references.pmid: 21210753
references.citation: Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9
references.pmid: 11301370
references.citation: Science. 1993 Jul 9;261(5118):212-5
references.pmid: 8327892
references.citation: Oncogene. 1998 Oct 29;17(17):2235-49
references.pmid: 9811454
references.citation: J Biomol Screen. 2004 Sep;9(6):506-15
references.pmid: 15452337
references.citation: Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70
references.pmid: 10482195
references.citation: Ann Oncol. 2012 Aug;23(8):2153-2161
references.pmid: 22234739
references.citation: Br J Cancer. 2006 Aug 7;95(3):289-97
references.pmid: 16868547
references.citation: Nano Lett. 2007 Nov;7(11):3305-14
references.pmid: 17918903
references.citation: J Cancer Ther. 2011 Mar;2(1):22-39
references.pmid: 26229727
references.citation: Clin Cancer Res. 2007 May 1;13(9):2795-803
references.pmid: 17473213
references.citation: Cancer Chemother Pharmacol. 2005 May;55(5):425-32
references.pmid: 15565325
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(5):809-17
references.pmid: 17581752
references.citation: Reprod Biol Endocrinol. 2007 Sep 25;5:38
references.pmid: 17894888
references.citation: Mol Cancer Ther. 2002 Nov;1(13):1201-9
references.pmid: 12479701
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1794-803
references.pmid: 16551864
references.citation: J Egypt Natl Canc Inst. 2006 Sep;18(3):209-15
references.pmid: 17671530
references.citation: Cancer Chemother Pharmacol. 1999;44(2):117-23
references.pmid: 10412945
references.citation: J Chromatogr B Biomed Appl. 1996 Jun 28;682(1):115-23
references.pmid: 8832432
references.citation: Bioorg Med Chem. 2011 Jan 1;19(1):67-76
references.pmid: 21169024
references.citation: Oncology. 2001;61 Suppl 2:50-7
references.pmid: 11694788
references.citation: Anticancer Drugs. 2001 Feb;12(2):107-16
references.pmid: 11261883
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6567-71
references.pmid: 14695162
references.citation: Mol Cancer Ther. 2004 Mar;3(3):279-90
references.pmid: 15026548
references.citation: J Drug Target. 2009 Jul;17(6):474-89
references.pmid: 19480561
references.citation: Neurosurgery. 2000 Mar;46(3):704-9
references.pmid: 10719867
references.citation: Clin Cancer Res. 2004 May 1;10(9):2936-43
references.pmid: 15131028
references.citation: Eur J Cancer. 2003 Jul;39(11):1547-51
references.pmid: 12855261
references.citation: Anticancer Res. 2002 May-Jun;22(3):1369-77
references.pmid: 12168813
references.citation: Clin Cancer Res. 1999 Feb;5(2):439-43
references.pmid: 10037195
references.citation: Mol Cancer Res. 2008 Aug;6(8):1308-15
references.pmid: 18667591
references.citation: Cancer. 2013 Apr 15;119(8):1555-61
references.pmid: 23335221
references.citation: Cancer Immunol Immunother. 2009 Nov;58(11):1887-96
references.pmid: 19340424
references.citation: Cardiovasc Toxicol. 2007;7(2):122-8
references.pmid: 17652816
references.citation: J Chemother. 2008 Oct;20(5):632-9
references.pmid: 19028628
references.citation: Br J Cancer. 2008 Sep 2;99(5):760-7
references.pmid: 18728667
references.citation: Mol Biother. 1989;1(3):170-4
references.pmid: 2604916
references.citation: Chembiochem. 2009 Mar 23;10(5):862-8
references.pmid: 19253922
references.citation: Anticancer Res. 2005 May-Jun;25(3A):1531-7
references.pmid: 16033055
references.citation: Proc Natl Acad Sci U S A. 1989 May;86(10):3778-81
references.pmid: 2786202
references.citation: Mol Cancer Ther. 2010 May;9(5):1286-97
references.pmid: 20457621
references.citation: Herz. 2000 Nov;25(7):676-88
references.pmid: 11141677
references.citation: Oncology. 2001;61(1):42-6
references.pmid: 11474247
references.citation: Eur J Pharm Sci. 2004 Dec;23(4-5):393-7
references.pmid: 15567293
references.citation: Bioorg Med Chem. 1999 Nov;7(11):2517-24
references.pmid: 10632061
references.citation: Cancer Chemother Pharmacol. 2001 Dec;48(6):493-8
references.pmid: 11800031
references.citation: J Control Release. 2008 Dec 18;132(3):171-83
references.pmid: 18582981
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4909-19
references.pmid: 17699871
references.citation: Cell Rep. 2013 Jun 27;3(6):2008-20
references.pmid: 23770238
references.citation: Cancer Invest. 2009 Feb;27(2):171-7
references.pmid: 19235589
references.citation: Acta Biomater. 2010 Jun;6(6):1968-77
references.pmid: 20025999
references.citation: J Biomed Mater Res B Appl Biomater. 2010 Jul;94(1):187-95
references.pmid: 20524194
references.citation: J Drug Target. 2003 Feb;11(2):101-7
references.pmid: 12881196
references.citation: Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100
references.pmid: 11236023
references.citation: Mol Oncol. 2013 Jun;7(3):379-91
references.pmid: 23228483
references.citation: Cancer Clin Oncol. 2012 Nov;1(2):49-80
references.pmid: 26225190
references.citation: Science. 1986 Jan 10;231(4734):148-50
references.pmid: 3484557
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):600-7
references.pmid: 16428506
references.citation: Clin Pharmacokinet. 2005;44(9):957-67
references.pmid: 16122282
references.citation: BMC Cancer. 2010 Jul 30;10:397
references.pmid: 20673348
references.citation: Anticancer Res. 2004 May-Jun;24(3b):2079-83
references.pmid: 15274404
references.citation: Mol Cancer. 2006 Sep 05;5:34
references.pmid: 16953886
references.citation: Lung Cancer. 2003 Oct;42(1):97-102
references.pmid: 14512193
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):871-9
references.pmid: 21177764
references.citation: Adv Exp Med Biol. 2007;608:1-22
references.pmid: 17993229
references.citation: J Med Chem. 2003 Sep 11;46(19):4205-8
references.pmid: 12954073
references.citation: Fundam Appl Toxicol. 1994 Feb;22(2):304-13
references.pmid: 8005380
references.citation: Anticancer Drugs. 1997 Feb;8(2):199-203
references.pmid: 9073316
references.citation: Nat Clin Pract Oncol. 2008 Sep;5(9):512-20
references.pmid: 18594499
references.citation: Cancer Res. 1986 Oct;46(10):4886-91
references.pmid: 2428468
references.citation: Bioorg Med Chem Lett. 2009 Aug 15;19(16):4764-7
references.pmid: 19574048
references.citation: Br J Cancer. 2011 Sep 6;105(6):796-806
references.pmid: 21847123
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: Anticancer Drugs. 2000 Jun;11(5):377-84
references.pmid: 10912954
references.citation: Yao Xue Xue Bao. 1992;27(5):325-30
references.pmid: 1442051
references.citation: Mol Pharm. 2006 Nov-Dec;3(6):737-44
references.pmid: 17140261
references.citation: Biomed Pharmacother. 2004 Nov;58(9):520-6
references.pmid: 15511610
references.citation: Anticancer Res. 1995 Jul-Aug;15(4):1387-93
references.pmid: 7654026
references.citation: Biotherapy. 1997;10(2):145-59
references.pmid: 9373737
references.citation: Cancer Immunol Immunother. 1994 Feb;38(2):92-8
references.pmid: 8306371
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3709-14
references.pmid: 18669456
references.citation: Cancer Chemother Pharmacol. 2005 Jul;56(1):15-21
references.pmid: 15789226
references.citation: Anticancer Agents Med Chem. 2009 Jul;9(6):703-15
references.pmid: 19601750
references.citation: Cancer Res. 2009 Mar 15;69(6):2191-4
references.pmid: 19276389
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6730-4
references.pmid: 18980964
references.citation: Bioorg Med Chem. 1995 Oct;3(10):1305-12
references.pmid: 8564396
references.citation: Cancer Lett. 2013 Jul 10;335(1):153-9
references.pmid: 23402816
references.citation: Anticancer Res. 2010 Feb;30(2):473-80
references.pmid: 20332457
references.citation: Ann Oncol. 2011 Jun;22(6):1308-1317
references.pmid: 21119031
references.citation: Mol Cancer Ther. 2009 Nov;8(11):3015-23
references.pmid: 19887555
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: PLoS One. 2009 Oct 02;4(10):e7287
references.pmid: 19806185
references.citation: Rev Recent Clin Trials. 2007 May;2(2):111-6
references.pmid: 18473995
references.citation: Int J Cancer. 2004 Nov 10;112(3):492-501
references.pmid: 15382077
references.citation: Oncol Rep. 2010 May;23(5):1469-75
references.pmid: 20372866
references.citation: Cancer Res. 1990 Oct 15;50(20):6600-7
references.pmid: 2208122
references.citation: Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):720-5
references.pmid: 18600531
references.citation: Mol Biother. 1989;1(5):250-5
references.pmid: 2515870
references.citation: Eur J Med Chem. 2008 Jun;43(6):1336-43
references.pmid: 17949859
references.citation: Bioconjug Chem. 1991 May-Jun;2(3):133-41
references.pmid: 1932212
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4858-66
references.pmid: 17699865
references.citation: Cancer Biother Radiopharm. 2012 Feb;27(1):41-55
references.pmid: 22191802
references.citation: Anticancer Res. 2010 Nov;30(11):4673-7
references.pmid: 21115922
references.citation: Mol Pharm. 2010 Dec 6;7(6):2255-69
references.pmid: 20958082
references.citation: J Pharmacol Exp Ther. 2011 May;337(2):423-32
references.pmid: 21262849
references.citation: Med Oncol. 2012 Jun;29(2):761-7
references.pmid: 21298497
references.citation: Neurosurgery. 2003 Dec;53(6):1406-12; discussion 1412-3
references.pmid: 14633307
references.citation: J Org Chem. 1999 Oct 29;64(22):8319-8322
references.pmid: 11674754
references.citation: Bioorg Med Chem Lett. 2005 May 16;15(10):2571-4
references.pmid: 15863318
references.citation: Biochem Pharmacol. 2010 Jul 1;80(1):72-9
references.pmid: 20298675
references.citation: J Clin Exp Oncol. 2013;2(2):
references.pmid: 26251840
references.citation: Cancer Res. 2002 Apr 1;62(7):2034-42
references.pmid: 11929822
references.citation: BMC Cancer. 2010 Apr 15;10:143
references.pmid: 20398289
references.citation: Clin Cancer Res. 2002 Sep;8(9):2963-9
references.pmid: 12231542
references.citation: Tumour Biol. 1991;12(4):198-206
references.pmid: 1651554
references.citation: Cancer Immunol Immunother. 1988;27(3):267-71
references.pmid: 3180150
references.citation: Int J Oncol. 2010 Sep;37(3):669-78
references.pmid: 20664936
references.citation: Clin Cancer Res. 1999 Apr;5(4):909-16
references.pmid: 10213228
references.citation: Toxicol In Vitro. 2008 Feb;22(1):232-9
references.pmid: 17904330
references.citation: Cancer Res. 1997 Oct 15;57(20):4530-6
references.pmid: 9377565
references.citation: Chemotherapy. 2010;56(4):303-12
references.pmid: 20714148
references.citation: Exp Oncol. 2009 Jun;31(2):123-4
references.pmid: 19550405
references.citation: Invest New Drugs. 2007 Aug;25(4):313-26
references.pmid: 17483874
references.citation: Blood. 2010 Jun 10;115(23):4824-33
references.pmid: 20348394
references.citation: Bone Marrow Transplant. 2001 Mar;27(5):531-6
references.pmid: 11313688
references.citation: Biochem J. 1996 Nov 15;320 ( Pt 1):293-300
references.pmid: 8947500
references.citation: Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76
references.pmid: 11561783
references.citation: Int J Pharm. 2010 May 31;391(1-2):212-20
references.pmid: 20214970
references.citation: Expert Rev Anticancer Ther. 2008 Dec;8(12):1859-69
references.pmid: 19046106
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33
references.pmid: 18713866
references.citation: Anticancer Res. 2000 Mar-Apr;20(2A):799-808
references.pmid: 10810357
references.citation: Curr Cancer Drug Targets. 2010 Dec;10(8):824-33
references.pmid: 20718704
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5257-64
references.pmid: 16033844
references.citation: Cancer Chemother Pharmacol. 2006 Jan;57(1):105-13
references.pmid: 16133534
references.citation: Curr Med Chem. 2011;18(3):329-41
references.pmid: 21143122
references.citation: J Med Chem. 2002 Dec 5;45(25):5523-33
references.pmid: 12459020
references.citation: Biochem Pharmacol. 2007 Aug 1;74(3):407-14
references.pmid: 17560963
references.citation: J Drug Target. 2002 Nov;10(7):567-71
references.pmid: 12683724
references.citation: Biotechnol Appl Biochem. 2005 Apr;41(Pt 2):137-43
references.pmid: 15202936
references.citation: Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9
references.pmid: 21402055
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6304-12
references.pmid: 21810918
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Pharm Biomed Anal. 2003 Dec 4;33(5):1093-102
references.pmid: 14656600
references.citation: Pharmacol Ther. 2010 Feb;125(2):196-218
references.pmid: 19874849
references.citation: Tumour Biol. 2010 Aug;31(4):233-42
references.pmid: 20556593
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3407-13
references.pmid: 22553344
references.citation: Cancer Lett. 2001 Apr 10;165(1):43-9
references.pmid: 11248417
references.citation: J Neurooncol. 2003 Oct;65(1):49-62
references.pmid: 14649885
references.citation: Biomaterials. 2009 Jul;30(20):3466-75
references.pmid: 19304320
references.citation: Cancer Chemother Pharmacol. 2009 Jul;64(2):413-8
references.pmid: 19229536
references.citation: Biochem Biophys Res Commun. 2003 Apr 4;303(2):556-61
references.pmid: 12659854
references.citation: Curr Pharm Des. 2005;11(9):1079-89
references.pmid: 15853657
references.citation: Clin Ther. 2008 Aug;30(8):1426-47
references.pmid: 18803986
references.citation: Cancer Immunol Immunother. 2007 Jan;56(1):35-47
references.pmid: 16636810
references.citation: Anticancer Res. 2001 Mar-Apr;21(2B):1301-5
references.pmid: 11396203
references.citation: Anticancer Drugs. 2006 Jan;17(1):53-61
references.pmid: 16317290
references.citation: Biochem Biophys Res Commun. 1981 Oct 15;102(3):1048-54
references.pmid: 7306187
references.citation: J Biol Chem. 2011 May 27;286(21):19127-37
references.pmid: 21471222
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1993-9
references.pmid: 18421051
references.citation: Cancer Res. 1995 Jun 1;55(11):2352-6
references.pmid: 7757986
references.citation: Cancer Res. 2006 Oct 15;66(20):10100-11
references.pmid: 17047074
references.citation: Cancer Chemother Pharmacol. 2012 May;69(5):1117-26
references.pmid: 22205203
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Cancer Lett. 2010 Aug 28;294(2):211-9
references.pmid: 20193978
references.citation: Bioconjug Chem. 2008 Jul;19(7):1414-22
references.pmid: 18578486
references.citation: Proc Natl Acad Sci U S A. 1988 Feb;85(4):1189-93
references.pmid: 3422487
references.citation: Chemotherapy. 2008;54(3):194-200
references.pmid: 18560226
references.citation: Bioorg Med Chem Lett. 2005 Nov 15;15(22):5071-5
references.pmid: 16168650
references.citation: Breast Cancer Res. 2011 Apr 21;13(2):R46
references.pmid: 21510863